DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced consolidated results for the second quarter of 2008 and for the six-month period ended June 30, 2008. Strong sales of Neoprobe’s gamma detection devices resulted in second quarter 2008 revenue of $2.3 million and a gross margin of over $1.3 million. For the second quarter of 2008, Neoprobe reported a net loss of $1.0 million or $0.01 per share compared to a net loss of $1.1 million or $0.02 per share for the second quarter in 2007. For the six months ended June 30, 2008, Neoprobe reported a net loss of $2.0 million or $0.03 per share compared to a net loss of $2.2 million or $0.04 per share for the same period in 2007. Neoprobe’s Loss from Operations for the second quarter of 2008 was $454,000 compared to $708,000 for the second quarter of 2007. Neoprobe’s Loss from Operations for the six-month period ended June 30, 2008 was $771,000 compared to $1.4 million for the same period of 2007.
